Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 1/2016

01-01-2016 | Letter to the Editor

Reply to the letter by Fujishiro et al. concerning “Controversy regarding gastric cancer and diabetes”

Authors: Akira Sekikawa, Hirokazu Fukui, Takanori Maruo, Takehiko Tsumura, Yukio Osaki

Published in: Journal of Gastroenterology | Issue 1/2016

Login to get access

Excerpt

We thank Fujishiro et al. for their interest in our recently published article [1] and for their insightful comments. Several reports have focused on the association between diabetes mellitus (DM) and the risk of gastric cancer [2, 3]. In previous studies, however, the criteria for both DM and the diagnosis of gastric cancer varied, which means that any results suggesting an association between DM and gastric cancer development remain controversial. Our endoscopic follow-up study clearly showed that the presence of DM diagnosed on the basis of medical history and/or serological examination was associated with the development of early gastric cancer [4]. …
Literature
1.
Seikawa A, Fukui H, Sada R, et al. Gastric atrophy and xanthelasma are marker for predicting the development of gastric cancer. J Gastroenterol. 2015;. doi:10.​1007/​s00535-015-1081-0.
2.
Ikeda F, Doi Y, Yonemoto K, et al. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology. 2009;136:1234–41.PubMedCrossRef
3.
4.
Sekikawa A, Fukui H, Maruo T, et al. Diabetes mellitus increases the risk of early gastric cancer development. Eur J Cancer. 2014;50:2065–71.PubMedCrossRef
5.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.PubMedCrossRef
Metadata
Title
Reply to the letter by Fujishiro et al. concerning “Controversy regarding gastric cancer and diabetes”
Authors
Akira Sekikawa
Hirokazu Fukui
Takanori Maruo
Takehiko Tsumura
Yukio Osaki
Publication date
01-01-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1115-7

Other articles of this Issue 1/2016

Journal of Gastroenterology 1/2016 Go to the issue

Erratum

Erratum to: NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers

Review

Recurrent Clostridium difficile infection and the microbiome

Original Article—Liver, Pancreas, and Biliary Tract

The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

Original Article—Alimentary Tract

Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer

Letter to the Editor

Controversy regarding gastric cancer and diabetes

ORIGINAL ARTICLE—ALIMENTARY TRACT

NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits